Citations

Showing 10 of 108104 citations.

Evidence-Based Disparities in Stroke Care Metrics and Outcomes in the United States: A Systematic Review
Ikeme, Shelly , Kottenmeier, Emilie , Uzochukwu, Goldfield , Brinjikji, Waleed , Ikeme, Shelly , Kottenmeier, Emilie , Uzochukwu, Goldfield , Brinjikji, Waleed

Mayo Clinic

Stroke | February 2, 2022 | Volume: 53 | Issue: 3 | Pages: 670-679

10.1161/strokeaha.121.036263 | PMID 35105178 Get It

Stroke disproportionately affects racial minorities, and the level to which stroke treatment practices differ across races is understudied. Here, we performed a systematic review of disparities in stroke treatment between racial minorities and White patients. A systematic literature search was performed on PubMed to identify studies published from January 1, 2010, to April 5, 2021 that investigated disparities in access to stroke treatment between racial minorities and White patients. A total of 30 studies were included in the systematic review. White patients were estimated to use emergency medical services at a greater rate (59.8%) than African American (55.6%), Asian (54.7%), and Hispanic patients (53.2%). A greater proportion of White patients (37.4%) were estimated to arrive within 3 hours from onset of stroke symptoms than African American (26.0%) and Hispanic (28.9%) patients. A greater proportion of White patients (2.8%) were estimated to receive tPA (tissue-type plasminogen activator) as compared with African American (2.3%), Hispanic (2.6%), and Asian (2.3%) patients. Rates of utilization of mechanical thrombectomy were also lower in minorities than in the White population. As shown in this review, racial disparities exist at key points along the continuum of stroke care from onset of stroke symptoms to treatment. Beyond patient level factors, these disparities may be attributed to other provider and system level factors within the health care ecosystem.
Impact of conditioning regimen intensity on the outcomes of peripheral T‐cell lymphoma, anaplastic large cell lymphoma and angioimmunoblastic T‐cell lymphoma patients undergoing allogeneic transplant
Ahn, Kwang Woo , Ahmed, Sairah , Cashen, Amanda F. , Modi, Dipenkumar , Khimani, Farhad , Zain, Jasmine , Brammer, Jonathan E. , Rezvani, Andrew R. , Fenske, Timothy S. , Sauter, Craig S. , Kharfan‐Dabaja, Mohamed A. , Herrera, Alex F. , Savani, Malvi , Ahmed, Sairah , Modi, Dipenkumar , Hamadani, Mehdi , Chen, Yue , Shadman, Mazyar , Cutler, Corey S. , Hamadani, Mehdi

Mayo Clinic

British Journal of Haematology | February 2, 2022 | Volume: 197 | Issue: 2 | Pages: 212-222

10.1111/bjh.18052 | PMID 35106754 Get It

SummaryThere have been no large studies comparing reduced‐intensity/non‐myeloablative conditioning (RIC/NMA) to myeloablative conditioning (MAC) regimens in T‐cell non‐Hodgkin lymphoma (T‐NHL) patients undergoing allogeneic transplant (allo‐HCT). A total of 803 adults with peripheral T‐cell lymphoma, anaplastic large cell lymphoma and angioimmunoblastic T‐cell lymphoma (age 18–65 years), undergoing allo‐HCT between 2008–2019 and reported to the Center for International Blood and Marrow Transplant Research with either MAC (n = 258) or RIC/NMA regimens (n = 545) were evaluated. There were no significant differences between the two cohorts in terms of patient sex, race and performance scores. Significantly more patients in the RIC/NMA cohort had peripheral blood grafts, haematopoietic cell transplantation‐specific comorbidity index (HCT‐CI) of ≥3 and chemosensitive disease compared to the MAC cohort. On multivariate analysis, overall survival (OS) was not significantly different in the RIC/NMA cohort compared to the MAC cohort (hazard ratio (HR) = 1.01, 95% confidence interval (CI) = 0.79–1.29; p = 0.95). Similarly, non‐relapse mortality (NRM) (HR = 0.85, 95% CI = 0.61–1.19; p = 0.34), risk of progression/relapse (HR = 1.29; 95% CI = 0.98–1.70; p = 0.07) and therapy failure (HR = 1.14; 95% CI = 0.92–1.41, p = 0.23) were not significantly different between the two cohorts. Relative to MAC, RIC/NMA was associated with a significantly lower risk of grade 3–4 acute graft‐versus‐host disease (HR = 0.67; 95% CI = 0.46–0.99, p = 0.04). Among chemorefractory patients, there was no difference in OS, therapy failure, relapse, or NRM between RIC/NMA and MAC regimens. In conclusion, we found no association between conditioning intensity and outcomes after allo‐HCT for T‐cell NHL.
MRI imaging versus histologic volumetric estimation of residual injection laryngoplasty material
Bowen, Andrew J. , San‐Marina, Serban , Hunter, Danielle E., Voss, Stephen G. , Meloche, Ryan , Spragg, Andrew Mearns, Lohse, Christine M. , Oldenburg, Michael , Ekbom, Dale C. , Bowen, Andrew Jay , Hunter, Danielle, Voss, Stephen , Macura, Slobodan , Lohse, Christine, Ekbom, Dale , Bartemes, Kathleen R.

Mayo Clinic

Laryngoscope Investigative Otolaryngology | February 2, 2022 | Volume: 7 | Issue: 2 | Pages: 454-459

10.1002/lio2.744 | PMID 35434315 Get It

AbstractObjectivesTo examine the degree of agreement between MRI and histologically generated volumetric measurements of residual injection laryngoplasty material.MethodsFollowing left recurrent laryngeal nerve transection, rabbit vocal cords were injected with jellyfish collagen, Cymetra®, or Restylane®. Laryngeal tissue was harvested 4 or 12 weeks post injection followed by MRI imaging and histologic cross‐sectioning. Two raters estimated the volume of remaining injection material in specimens within MRI and histologic axial cross sections. Wilcoxon signed rank tests were employed to detect gross differences between inter‐rater measurements and between imaging modalities across time. Agreement between rater measurements and imaging (histology and MRI) was assessed using intra‐class correlation coefficients.ResultsData was available from 16 rabbits sacrificed at 4 weeks (n = 8) and 12 weeks (n = 8). Inter‐rater testing of MRI imaging revealed no significant differences (p > .05) between rater measurements across time points, and excellent agreement (0.93; 95% confidence interval 0.80–0.98) while histologically estimated volumes demonstrated a significant difference at 4 weeks (p < .05) and overall good agreement (0.89; 95% confidence interval 0.59–0.97). Comparison of MRI and histologically estimated volume measurements revealed significant differences at the 4‐week time point (p < .05) but not at 12 weeks (p > .05). Overall, there is only moderate agreement between MRI and histology estimates (0.72; 95% confidence interval 0.22–0.90).ConclusionsMRI imaging demonstrates good reliability and similar estimates of volume to histologically estimated measurements of residual injection laryngoplasty material at time points clinically relevant for future injection laryngoplasty experiments.Level of EvidenceNA.
When the Sun Sets, Who Doth Not Look for Night?
Ryan, Randi J., Taner, Timuçin , Heimbach, Julie K. , Heimbach, Julie K , Ryan, Randi J.

Mayo Clinic

Liver Transplantation | February 2, 2022 | Volume: 28 | Issue: 5 | Pages: 747-748

10.1002/lt.26423 | PMID 35106929 Get It

Mending the Model for End‐Stage Liver Disease: An in‐depth review of the past, present, and future portopulmonary hypertension Model for End‐Stage Liver Disease exception
DuBrock, Hilary M. , Valle, Kathryn T. del , Krowka, Michael J. , DuBrock, Hilary M , Del Valle, Kathryn T

Mayo Clinic

Liver Transplantation | February 2, 2022 | Volume: 28 | Issue: 7 | Pages: 1224-1230

10.1002/lt.26422 | PMID 35106916 Get It

Abstract Patients with portopulmonary hypertension (POPH) have an increased cardiovascular and overall mortality risk when undergoing liver transplantation (LT). However, such risk is not captured in their Model for End‐Stage Liver Disease (MELD) laboratory score. POPH MELD exception criteria were established in 2006 with the aim of prioritizing these patients for LT prior to pulmonary hypertension (PH) progression and eventual right heart failure. The original criteria emphasized a posttreatment, pre‐LT mean pulmonary arterial pressure (mPAP) of <35 mm Hg and pulmonary vascular resistance (PVR) <400 dynes‐s‐cm−5 or <5 Wood units (WU). Since 2006, there have been important advances in the treatment of POPH with pulmonary arterial hypertension (PAH)–targeted therapies and newer evidence regarding LT outcomes and risk factors for perioperative mortality. Specifically, PVR rather than mPAP has been shown to be more strongly associated with outcomes, including mortality. In addition, among treated patients with POPH, mPAP may be persistently elevated related to an elevated cardiac output or other factors that do not necessarily reflect POPH disease severity. Thus, in February 2021, the Organ Procurement and Transplantation Network approved proposed modifications to POPH MELD exception criteria, now allowing either of the following posttreatment, pre‐LT hemodynamic profiles: mPAP less than 35 mm Hg and posttreatment PVR less than 400 dynes‐s‐cm−5 (or less than 5 WU) or mPAP greater than or equal to 35 mm Hg and less than 45 mm Hg and posttreatment PVR less than 240 dynes‐s‐cm−5 (or less than 3 WU). This article reviews the history of the POPH MELD exception criteria, describes the recent modifications to the exception criteria and the evidence supporting them, and highlights unanswered questions and areas for future research.
Metabolic Complications of Chronic HIV Infection: A Narrative Review
Cummins, Nathan W.

Mayo Clinic

Pathogens | February 1, 2022 | Volume: 11 | Issue: 2 | Pages: 197

10.3390/pathogens11020197 | PMID 35215140 Get It

As persons who are HIV positive and on suppressive antiretroviral therapy live longer, there is increased incidence and recognition of several metabolic complications of this chronic infection. These metabolic complications of HIV infection can result from the infection itself and/or otherwise effective antiviral treatment and can have significant impacts on morbidity and mortality. Some metabolic complications of HIV infection are preventable but most are modifiable, and therefore, active surveillance and screening are warranted. The purpose of this narrative review is to highlight the most common metabolic complications of chronic HIV infection, associated risk factors, diagnosis, and management.
Machine learning and conventional statistics: making sense of the differences
Ley, Christophe , Martin, R. Kyle , Pareek, Ayoosh , Tischer, Thomas , Groll, Andreas , Seil, Romain

Mayo Clinic

Knee Surgery, Sports Traumatology, Arthroscopy | February 1, 2022 | Volume: 30 | Issue: 3 | Pages: 753-757

10.1007/s00167-022-06896-6 | PMID 35106604 Get It

AbstractThe application of machine learning (ML) to the field of orthopaedic surgery is rapidly increasing, but many surgeons remain unfamiliar with the nuances of this novel technique. With this editorial, we address a fundamental topic—the differences between ML techniques and traditional statistics. By doing so, we aim to further familiarize the reader with the new opportunities available thanks to the ML approach.
Genome-wide association study reveals novel genetic loci: a new polygenic risk score for mitral valve prolapse
Roselli, Carolina , Yu, Mengyao , Nauffal, Victor , Georges, Adrien , Love, Katie , Weng, Lu‐Chen , Delling, Francesca N. , Maurya, Svetlana , Schrölkamp, Maren , Tfelt‐Hansen, Jacob , Jeunemaı̂tre, Xavier , Debette, Stéphanie , Guan, Wyliena , Body, Simon C. , Shah, Svati H. , Samad, Zainab , Kyryachenko, Sergiy , Haynes, Carol , Rienstra, Michiel , Hamer, Inez J. Wijdh‐den , Siland, Joylene E. , Levine, Robert A. , Benjamin, Emelia J. , Horne, Benjamin D. , Muhlestein, Joseph B. , Benfari, Giovanni , Natale, Andrea , Trivedi, Chintan , Shoemaker, Moore B., Yoneda, Zachary T. , Baker, Michael , Slaugenhaupt, Susan, Dina, Christian , Lubitz, Steven A. , Bouatia‐Naji, Nabila , Milan, David J. , Yang, Qiong , Love, Katie , Weng, Lu-Chen , Delling, Francesca N , Maurya, Svetlana R , Schrölkamp, Maren , Tfelt-Hansen, Jacob , Debette, Stephanie , Amouyel, Philippe , Guan, Wyliena , Muehlschlegel, Jochen D , Body, Simon C , Shah, Svati , Kyryachenko, Sergiy , Haynes, Carol , Rienstra, Michiel , Le Tourneau, Thierry , Wijdh-Den Hamer, Inez J , Siland, Joylene E , Jacques Schott, Jean , Levine, Robert A , Benjamin, Emelia J , Vasan, Ramachandran S , Horne, Benjamin D , Muhlestein, Joseph B , Benfari, Giovanni , Enriquez-Sarano, Maurice , Yoneda, Zachary T , Baker, Michael T , Farber-Eger, Eric H , Norris, Russell A , Dina, Christian , Lubitz, Steven A , Bouatia-Naji, Nabila , Ellinor, Patrick T , Natale, Andrea , Hagège, Albert Alain , Amouyel, Philippe , Tourneau, Thierry Le , Probst, Vincent , Roussel, Ronan , Knowlton, Kirk U. , Schott, Jean‐Jacques , Vasan, Ramachandran S. , Enriquez‐Sarano, Maurice , Mohanty, Sanghamitra , Wells, Quinn S. , Farber‐Eger, Eric , Michelena, Héctor I. , Lundby, Alicia , Ellinor, Patrick T.

Mayo Clinic

European Heart Journal | February 1, 2022 | Volume: 43 | Issue: 17 | Pages: 1668-1680

10.1093/eurheartj/ehac049 | PMID 35245370 Get It

Abstract Aims Mitral valve prolapse (MVP) is a common valvular heart disease with a prevalence of &gt;2% in the general adult population. Despite this high incidence, there is a limited understanding of the molecular mechanism of this disease, and no medical therapy is available for this disease. We aimed to elucidate the genetic basis of MVP in order to better understand this complex disorder. Methods and results We performed a meta-analysis of six genome-wide association studies that included 4884 cases and 434 649 controls. We identified 14 loci associated with MVP in our primary analysis and 2 additional loci associated with a subset of the samples that additionally underwent mitral valve surgery. Integration of epigenetic, transcriptional, and proteomic data identified candidate MVP genes including LMCD1, SPTBN1, LTBP2, TGFB2, NMB, and ALPK3. We created a polygenic risk score (PRS) for MVP and showed an improved MVP risk prediction beyond age, sex, and clinical risk factors. Conclusion We identified 14 genetic loci that are associated with MVP. Multiple analyses identified candidate genes including two transforming growth factor-β signalling molecules and spectrin β. We present the first PRS for MVP that could eventually aid risk stratification of patients for MVP screening in a clinical setting. These findings advance our understanding of this common valvular heart disease and may reveal novel therapeutic targets for intervention.
CT or MR Enterography to Assess Response During Vedolizumab Therapy for Small Bowel Crohn’s Disease
Kwapisz, Lukasz , Bruining, David H. , Lee, Yong S. , Edwards, Phillip K , Holmes, David R. , Carter, Rickey E. , Siegelman, Jenifer , Fletcher, Joel G. , Inoue, Akitoshi , Fletcher, Joel G , Carter, Rickey E

Mayo Clinic

Crohn's & Colitis 360 | February 1, 2022 | Volume: 4 | Issue: 1 | Pages: No page available

10.1093/crocol/otac003 | PMID 36777547 Get It

Abstract Background To describe response to therapy of small bowel (SB) Crohn’s disease (CD) at CT or MR enterography (CTE/MRE) in patients on vedolizumab. Methods Patients with SB CD who underwent CTE/MRE exams greater than 12 months apart on vedolizumab therapy were included. Length (in cm) and inflammation severity (EMBARK score) of inflamed SB segments were assessed. Changes in inflammation length of 3.4 cm or greater or inflammation severity of 2 EMBARK points or greater was categorized as response or progression, as appropriate, with development of newly inflamed segments, strictures, or penetrating complications also indicating progression. Patients not meeting the criteria for response or progression were categorized as having stable disease. Results Of 36 SB CD patients, the large majority had prior surgery (86%; 31), anti-TNF use (92%; 33), and internal penetrating (78%; 28) disease. Thirty-two patients had paired baseline and follow-up CTE/MRE exams without interval surgery, with clinical response observed in 24/32 (75%). Based on imaging response criteria, 22% (7/32; 95% CI: 9%–40%) had response, 50% (16/32; 95% CI: 32%–68%) were stable, and 28% (9/32; 95% CI: 14%–47%) had disease progression. Fifty-six percent of (18/32; 95% CI: 38%–74%) patients had clinical improvement with response or stable disease by imaging. Patients with stable disease had shorter median baseline lengths of SB inflammation (P = .012). Proportion of patients with colonic inflammation, perianal disease, or penetrating complications did not change. Conclusions Most patients on vedolizumab for over 12 months demonstrated response or stable SB disease when using objective cross-sectional radiologic imaging criteria using CTE/MRE.
Characterizing neurofibrillary tangle maturity of phosphorylated tau fluid biomarkers in Alzheimer's disease
Tranovich, Jessica F., Siddiqui, Habeeba, Graff‐Radford, Neill R. , Lachner, Christian , Moloney, Christina M. , Labuzan, Sydney A. , Crook, Julia E. , Dickson, Dennis W. , Mielke, Michelle M. , Murray, Melissa E.

Mayo Clinic

Alzheimer's & Dementia | February 1, 2022 | Volume: 17 | Issue: S3 | Pages: No page available

10.1002/alz.056032 Get It